603 related articles for article (PubMed ID: 23419783)
21. Metformin: a new treatment option for non-insulin-dependent diabetes mellitus.
Goo AK; Carson DS; Bjelajac A
J Fam Pract; 1996 Jun; 42(6):612-8. PubMed ID: 8656173
[TBL] [Abstract][Full Text] [Related]
22. The effects of sulfonylureas plus metformin on lipids, blood pressure, and adverse events in type 2 diabetes: a meta-analysis of randomized controlled trials.
Zhang F; Xiang H; Fan Y; Ganchuluun TA; Kong W; Ouyang Q; Sun J; Cao B; Jiang H; Nie S
Endocrine; 2013 Dec; 44(3):648-58. PubMed ID: 23657947
[TBL] [Abstract][Full Text] [Related]
23. Pharmacologic Therapy of Diabetes and Overall Cancer Risk and Mortality: A Meta-Analysis of 265 Studies.
Wu L; Zhu J; Prokop LJ; Murad MH
Sci Rep; 2015 Jun; 5():10147. PubMed ID: 26076034
[TBL] [Abstract][Full Text] [Related]
24. Antidiabetic treatments and risk of hospitalisation with myocardial infarction: a nationwide case-control study.
Horsdal HT; Søndergaard F; Johnsen SP; Rungby J
Pharmacoepidemiol Drug Saf; 2011 Apr; 20(4):331-7. PubMed ID: 21442682
[TBL] [Abstract][Full Text] [Related]
25. The influence of antidiabetic medications on the development and progression of prostate cancer.
Hitron A; Adams V; Talbert J; Steinke D
Cancer Epidemiol; 2012 Aug; 36(4):e243-50. PubMed ID: 22417708
[TBL] [Abstract][Full Text] [Related]
26. Use of antidiabetic agents and the risk of pancreatic cancer: a case-control analysis.
Bodmer M; Becker C; Meier C; Jick SS; Meier CR
Am J Gastroenterol; 2012 Apr; 107(4):620-6. PubMed ID: 22290402
[TBL] [Abstract][Full Text] [Related]
27. Insulin in the early management of diabetic complications.
Miles JM
J Assoc Physicians India; 2003 May; 51():501-5. PubMed ID: 12974435
[TBL] [Abstract][Full Text] [Related]
28. Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?
Standl E; Schnell O
Diabetes Care; 2008 Feb; 31 Suppl 2():S136-9. PubMed ID: 18227474
[No Abstract] [Full Text] [Related]
29. Oral hypoglycemic agents in type II diabetes mellitus.
Lubbos H; Miller JL; Rose LI
Am Fam Physician; 1995 Nov; 52(7):2075-8. PubMed ID: 7484707
[TBL] [Abstract][Full Text] [Related]
30. Sulphonylureas and cancer: a case-control study.
Monami M; Lamanna C; Balzi D; Marchionni N; Mannucci E
Acta Diabetol; 2009 Dec; 46(4):279-84. PubMed ID: 19082520
[TBL] [Abstract][Full Text] [Related]
31. Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas.
Ragia G; Petridis I; Tavridou A; Christakidis D; Manolopoulos VG
Pharmacogenomics; 2009 Nov; 10(11):1781-7. PubMed ID: 19891554
[TBL] [Abstract][Full Text] [Related]
32. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
Comaschi M; Corsi A; Di Pietro C; Bellatreccia A; Mariz S;
Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):373-9. PubMed ID: 17919894
[TBL] [Abstract][Full Text] [Related]
33. Antidiabetic therapy and the risk of heart failure in type 2 diabetic patients: an independent effect or confounding by indication.
Koro CE; Bowlin SJ; Weiss SR
Pharmacoepidemiol Drug Saf; 2005 Oct; 14(10):697-703. PubMed ID: 15654719
[TBL] [Abstract][Full Text] [Related]
34. Are sulfonylurea and insulin therapies associated with a larger risk of cancer than metformin therapy? A retrospective database analysis.
Kowall B; Rathmann W; Kostev K
Diabetes Care; 2015 Jan; 38(1):59-65. PubMed ID: 25336750
[TBL] [Abstract][Full Text] [Related]
35. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies.
Rao AD; Kuhadiya N; Reynolds K; Fonseca VA
Diabetes Care; 2008 Aug; 31(8):1672-8. PubMed ID: 18458139
[TBL] [Abstract][Full Text] [Related]
36. Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: A network meta-analysis.
Tang H; Li G; Zhao Y; Wang F; Gower EW; Shi L; Wang T
Diabetes Obes Metab; 2018 May; 20(5):1262-1279. PubMed ID: 29369494
[TBL] [Abstract][Full Text] [Related]
37. Cardiovascular safety of metformin and sulfonylureas in patients with different cardiac risk profiles.
Wurm R; Resl M; Neuhold S; Prager R; Brath H; Francesconi C; Vila G; Strunk G; Clodi M; Luger A; Pacher R; Hülsmann M
Heart; 2016 Oct; 102(19):1544-51. PubMed ID: 27226327
[TBL] [Abstract][Full Text] [Related]
38. Comparative Impact of Hypoglycemic Agents on Severity and Extent of Myocardial Ischemia in Patients With Type 2 Diabetes Mellitus Undergoing Myocardial Perfusion Scintigraphy.
Biondi-Zoccai G; Pinto A; Versaci F; Procaccini E; Neri G; Sesti G; Uccioli L; Vetere M; Peruzzi M; Nudi F
J Cardiovasc Pharmacol; 2016 Aug; 68(2):162-70. PubMed ID: 27074768
[TBL] [Abstract][Full Text] [Related]
39. Time-Varying Risk for Breast Cancer Following Initiation of Glucose-Lowering Therapy in Women with Type 2 Diabetes: Exploring Detection Bias.
Bowker SL; Lin M; Eurich DT; Johnson JA
Can J Diabetes; 2017 Apr; 41(2):204-210. PubMed ID: 27908558
[TBL] [Abstract][Full Text] [Related]
40. Antihyperglycemic treatment in diabetics with coronary disease: increased metformin-associated mortality over a 5-year follow-up.
Fisman EZ; Tenenbaum A; Benderly M; Goldbourt U; Behar S; Motro M
Cardiology; 1999; 91(3):195-202. PubMed ID: 10516414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
